Kanjinti (trastuzumab) Injection 150 mg Single-Dose Vial
Kanjinti is a biosimilar to Herceptin (trastuzumab) used for the treatment of certain types of breast and gastric cancers. Each single-dose vial contains 150 mg of trastuzumab as a sterile, preservative-free solution for intravenous infusion. This product is supplied as a single vial for pharmacy preparation and administration.
Vendor Pricing Comparison
Sorted by lowest price · Add now, sign in at checkout
Vendor Pricing Comparison
Sorted by lowest price · Add now, sign in at checkout
Kanjinti is a biosimilar to Herceptin (trastuzumab) used for the treatment of certain types of breast and gastric cancers. Each single-dose vial contains 150 mg of trastuzumab as a sterile, preservative-free solution for intravenous infusion. This product is supplied as a single vial for pharmacy preparation and administration.
1 vendor
